Invivyd's Phase 3 Results, PEMGARDA Demonstrates Significant 6-Month COVID-19 Protection In Immunocompetent Participants Without Additional Doses
Portfolio Pulse from Benzinga Newsdesk
Invivyd's Phase 3 CANOPY trial results show that PEMGARDA provides significant COVID-19 protection for 12 months, with a 76% risk reduction in immunocompetent adults. The trial demonstrated strong efficacy and safety, even as drug concentrations declined.
October 29, 2024 | 11:13 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Invivyd's Phase 3 trial results for PEMGARDA show a 76% reduction in COVID-19 risk over 12 months, indicating strong efficacy and safety, which could positively impact the company's stock.
The Phase 3 trial results demonstrate significant efficacy and safety of PEMGARDA, which is likely to boost investor confidence in Invivyd. The 76% risk reduction over 12 months is a strong indicator of the drug's potential, likely leading to positive market reactions.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100